ArticleEuropean heart journal. Quality of care & clinical outcomes2022

Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden.

Ulf Landmesser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.